Skip to main content
Equibles
NXGL logo

NXGL · Nexgel, Inc. · Metrics

Track NXGL — free

Use NXGL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NXGL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.28 -0.05 (-0.94%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 17, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As of June 30, 2026, the Company had an unrestricted cash balance of $0.5 million. For the six months ended June 30, 2026, the Company incurred a net loss of $4.5 million and had a net usage of cash in operating activities of $2,701 thousand. These conditions raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 17, 2026
Market Cap
$2.60M
Shares
487,383
Volume · Oct 21 54.19K Avg daily vol (8 sessions) 496.7K

NXGL metrics

61 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$5.28
Market cap
$2.60M

Price action

20 metrics
Price change (1W)
+31.6%
Price change (30D)
+39.9%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Beta
—
RSI (14D)
—
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—

Company

3 metrics
Sector
Healthcare
Industry
Medical Instruments & Supplies
Shares outstanding
487,383

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.1×
reciprocal yield 951.8%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.2×
reciprocal yield 426.9%
P / book
0.6
reciprocal yield 175.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-220.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-11-12

Profitability

9 metrics
Gross margin
35.1%
Operating margin
-44.8%
Trailing 12 months
Net margin
-51.5%
Gross profit (TTM)
$4.23M
Operating profit (TTM)
−$5.40M
Net income (TTM)
−$6.22M
Trailing 12 months
Diluted EPS (TTM)
$-14.20
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$28.87
Gross profit per diluted share (TTM)
$10.18
Operating profit per diluted share (TTM)
$-12.70
EBITDA per diluted share (TTM)
$-10.06
Net income per diluted share (TTM)
$-14.43
Operating cash flow per diluted share (TTM)
$-7.38
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$1.51
Book value per share
$10.52

Growth

11 metrics
Revenue growth YoY
+27.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$12.07M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+17.8%
Year over year · more shares
Revenue CAGR (3Y)
+77.3%
Revenue CAGR (5Y)
+76.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-125.7%
Return on assets
-23.5%
Debt / equity
0.1
Current ratio
0.4
EBITDA (TTM)
−$4.25M
Free cash flow (TTM)
—
Quick ratio
0.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.56M
Latest balance sheet
Cash & equivalents
$1.71M
Total assets
$26.45M
Total debt
$563,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$3.21M
Capital expenditures (TTM)
—
R&D (TTM)
$21,000
SG&A (TTM)
$9.61M
Stock compensation (TTM)
$623,000
R&D / revenue
—
Stock compensation / revenue
5.2%

Ownership (13F)

9 metrics
13F filers
24
13F filer change QoQ
+2
Institutional ownership
15.0%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
3.4%
Private-fund adviser ownership
0.4%
Active holders' share change QoQ
+55.9%
Holder tenure
4.9
Price vs estimated holder cost
-50.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.7%

Short interest

3 metrics
Short interest
3.3%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
63 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1468929 CUSIP 65344E107 13F (30d) 1 filings 1 filers Visit website Investor relations